Company Presentation January 2013 - Epigenomics AG
Company Presentation January 2013 - Epigenomics AG
Company Presentation January 2013 - Epigenomics AG
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
<strong>Epigenomics</strong> at a Glance<br />
� <strong>Epigenomics</strong> is a leader in the field of DNA methylation based diagnostics for the early<br />
detection of cancer<br />
� <strong>Epigenomics</strong> has two promising commercial IVD tests with a CE mark:<br />
� <strong>Epigenomics</strong>’ near-term strategy is focused on obtaining FDA approval for Epi proColon®<br />
� <strong>Epigenomics</strong> completed its PMA filing of Epi pro Colon® to the FDA in 2012<br />
� A decision from the FDA is expected in the second half of <strong>2013</strong><br />
� <strong>Epigenomics</strong> is already building a customer base ahead of US approval. Currently over<br />
1,000 blood-based Septin9 laboratory-developed tests (LDT) are performed in the US weekly<br />
4 | <strong>January</strong> <strong>2013</strong><br />
� Addresses unmet need in the mass market of colorectal cancer (CRC)<br />
screening using the validated Septin9 biomarker<br />
� Is the first CE approved proprietary IVD test world wide that enables<br />
CRC screening based on a simple blood sample<br />
� Addresses unmet need in the niche market of difficult to diagnose lung<br />
cancer using the validated SHOX2 biomarker
Change language